Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a…
A new study has found that a certain type of diet, which has been previously hailed for its health benefits, could lead to raised levels…
This popular way of eating has been used by those looking to lose weight and control their blood sugar levels, but it could also have…
Alignment with the U.S. Global Water Strategy This topic aligns with Strategic Objective 3 in the U.S. Global Water Strategy: Improve Climate-Resilient Conservation and Management…
Background High levels of high-density lipoprotein cholesterol (HDL-C) are previously considered protective against cardiovascular diseases (CVD), but recent studies suggest an increased risk of adverse…
TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
Here’s how a glass a day could keep heart disease away
In low-blast, high-risk myeloid diseases, including myelodysplastic syndrome and chronic myelomonocytic leukemia, vibecotamab appeared well-tolerated.
AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features. Edited by Jennifer…
Research is central to improving outcomes of people diagnosed with and living with lung cancer. In 2025, LUNGevity is proud to continue our commitment to…
Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, placebo-cont…
